May 9, 2019
Takeda sells Xiidra to Novartis for up to $5.3B, TachoSil to Ethicon for $400M
Takeda sells Xiidra to Novartis for up to$5.3 billion, TachoSil to Ethicon for approximately $400 million
Pharmaceuticals, Biotechnology and Life Sciences
Tag: lifitegrast
October 19, 2015
Shire disappointed, wating lifitegrast, OPUS-3 study, data
“We were disappointed, but will soon have data from the Phase 3 study, OPUS 3,” said Flemming Ornskov, M.D., CEO, Shire.